5,284 Shares in Charles River Laboratories Intl. Inc (CRL) Purchased by Jane Street Group LLC

Jane Street Group LLC purchased a new stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 5,284 shares of the medical research company’s stock, valued at approximately $593,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. NumerixS Investment Technologies Inc bought a new position in Charles River Laboratories Intl. during the 2nd quarter valued at approximately $122,000. Wsfs Capital Management LLC bought a new position in Charles River Laboratories Intl. during the 2nd quarter valued at approximately $203,000. CIBC Private Wealth Group LLC bought a new position in Charles River Laboratories Intl. during the 2nd quarter valued at approximately $212,000. Dynamic Technology Lab Private Ltd bought a new position in Charles River Laboratories Intl. during the 2nd quarter valued at approximately $212,000. Finally, Visionary Asset Management Inc. bought a new position in Charles River Laboratories Intl. during the 2nd quarter valued at approximately $214,000. 97.78% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:CRL opened at $122.99 on Friday. Charles River Laboratories Intl. Inc has a 52-week low of $96.70 and a 52-week high of $135.90. The company has a market capitalization of $6.46 billion, a PE ratio of 23.34, a PEG ratio of 1.69 and a beta of 0.65. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, August 8th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The firm had revenue of $585.30 million during the quarter, compared to analyst estimates of $570.65 million. During the same quarter in the prior year, the company earned $1.29 EPS. The business’s revenue was up 24.8% compared to the same quarter last year. Equities research analysts forecast that Charles River Laboratories Intl. Inc will post 5.91 EPS for the current year.

CRL has been the subject of a number of recent analyst reports. Credit Suisse Group lowered their price target on Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating for the company in a research report on Tuesday, August 21st. Robert W. Baird upped their price target on Charles River Laboratories Intl. from $133.00 to $141.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Tuesday, August 28th. Raymond James raised Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 price target for the company in a research report on Thursday, August 23rd. Finally, Argus increased their target price on Charles River Laboratories Intl. from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, August 27th. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $128.50.

In related news, insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $120.05, for a total value of $149,942.45. Following the sale, the insider now owns 13,690 shares in the company, valued at approximately $1,643,484.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Birgit Girshick sold 3,978 shares of the company’s stock in a transaction that occurred on Tuesday, July 17th. The stock was sold at an average price of $119.90, for a total value of $476,962.20. Following the completion of the sale, the insider now owns 18,999 shares in the company, valued at approximately $2,277,980.10. The disclosure for this sale can be found here. Insiders sold a total of 32,019 shares of company stock valued at $3,914,826 in the last three months. Corporate insiders own 2.10% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: What kind of dividend yield to CEF’s pay?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply